Barinthus Biotherapeutics Plc share price logo

Barinthus Biotherapeutics Plc Share Price

NASDAQ: BRNS

Small Cap

$1.05

-0.05

(-4.55%)

as on

Barinthus Biotherapeutics Plc Stock Performance

as on September 16, 2025 at 1:27 am IST

  • Day's Low

    Day's High

    $1.04
    $1.12
    downward going graph

    0.95%

    Downside

    6.67%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.64
    $2.92
    downward going graph

    39.05%

    Downside

    178.10%

    Upside

    downward going graph

Barinthus Biotherapeutics Plc share price movements today

Previous Close
$1.10
Open
$1.10
Volume
419.9K
Day's Low - High
$1.04 - $1.12
52 Week Low - High
$0.64 - $2.92

Barinthus Biotherapeutics Plc Historical Returns

1 Month Return
-11.29 %
3 Month Return
+ 21.78 %
1 Year Return
-13.39 %
3 Year Return
0 %
5 Year Return
0 %

Barinthus Biotherapeutics Plc Stock Fundamentals & Key Indicators

Check Barinthus Biotherapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$44.8M

EPS (TTM)

-1.6433

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.71

Industry PE ratio

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-50.3M

Revenue (TTM)

15.0M

Profit Margin

0.00%

Return On Equity TTM

51453400.00%

Barinthus Biotherapeutics Plc Stock Valuation

Track how Barinthus Biotherapeutics Plc P/E has moved over time to understand its valuation trends.

Barinthus Biotherapeutics Plc in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Industry (0.00x)

September 15, 2025

Today (-0.71x)

September 15, 2025

Highest (-0.61x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.71x

Barinthus Biotherapeutics Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Barinthus Biotherapeutics Plc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$44.8MNA-0.710.00%
BUY$61.1B256.98%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$101.1B47.85%28.0731.86%
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Barinthus Biotherapeutics Plc Stock including INR - Dollar returns

The Barinthus Biotherapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Barinthus Biotherapeutics Plc investment value today

Current value as on today

₹87,663

Returns

₹12,337

(-12.34%)

Returns from Barinthus Biotherapeutics Plc Stock

₹17,323 (-17.32%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Barinthus Biotherapeutics Plc Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Barinthus Biotherapeutics Plc. Average target price of $4.5

Barinthus Biotherapeutics Plc Share Price Target

Get share price movements and forecasts by analysts on Barinthus Biotherapeutics Plc.

What analysts predicted

76.67%UPSIDE

Target Price

$4.5

Current Price

$1.05

Analyzed by

12 Analysts

Target

$4.50

Barinthus Biotherapeutics Plc target price $4.5, a slight upside of 76.67% compared to current price of $1.05. According to 12 analysts rating.

Barinthus Biotherapeutics Plc Stock's Interest Amongst Investors

Search interest for Barinthus Biotherapeutics Plc Stock has decreased by -86% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-86% versus previous 30 day period

Barinthus Biotherapeutics Plc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
0
0
-
5
-
-
14
-9
-
-
Gross Profit
0
-1
-1
3
-1
-1
14
-12
-2
-2
Operating Income
-21
-26
-16
-19
-16
-18
-9
46
-20
-23
EBITDA
-17
-23
-13
-16
-14
-15
-6
-19
-17
-19
Interest Expense
2
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
1
1
1
1
2
2
Income Before Tax
-18
-24
-14
-18
-15
-16
-8
-19
-19
-21
Income Tax Expense
0
-1
0
0
0
0
0
0
0
0
Net Income
-18
-23
-14
-17
-15
-16
-8
-20
-19
-21
Net Profit Margin
-3884.62%
-7126.35%
0.00%
-322.09%
0.00%
0.00%
-54.21%
223.81%
0.00%
0.00%

Barinthus Biotherapeutics Plc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
6
4
0
44
0
14
Gross Profit
6
4
0
44
-4
14
Operating Income
-25
-20
-45
-4
-83
-67
EBITDA
-22
-14
-47
6
-71
-55
Interest Expense
0
3
2
0
0
0
Depreciation
-
0
0
4
5
5
Income Before Tax
-22
-17
-51
0
-76
-61
Income Tax Expense
-2
0
0
-4
-3
0
Net Income
-20
-17
-50
5
-73
-61
Net Profit Margin
-302.85%
-367.27%
-18979.48%
11.95%
-9145.51%
-408.00%

Barinthus Biotherapeutics Plc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-23
-14
-17
-15
-16
-2
-20
-19
-21
Operating Cash Flow
-16
-11
-19
-11
-12
-18
13
-14
-18
Investing Cash Flow
-3
0
0
0
0
0
0
0
0
Financing Cash Flow
0
0
0
0
0
0
0
0
0
Change in Cash
-18
-12
-18
-12
-12
-11
6
-11
-12

Barinthus Biotherapeutics Plc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-17
-51
5
-73
-61
Operating Cash Flow
-11
-32
-14
-50
-28
Investing Cash Flow
0
-12
-5
-5
0
Financing Cash Flow
41
222
0
1
2
Change in Cash
31
170
-19
-52
-29

Global Institutional Holdings in Barinthus Biotherapeutics Plc

Funds
Holdings
M&G PLC
12.88%
Alphabet Inc
3.75%
SC China Holding Ltd
3.52%
DC Funds, LP
1.59%
The Johns Hopkins University
0.3%

Insights on Barinthus Biotherapeutics Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 182.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 87.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, BRNS stock has moved down by -8.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -19.64M → -21.12M (in $), with an average decrease of 7.5% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.96M → -9.17M (in $), with an average decrease of 161.3% per quarter

About Barinthus Biotherapeutics Plc

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit
OrganisationBarinthus Biotherapeutics Plc
HeadquartersZeus Building, Didcot, United Kingdom, OX11 0DF
CEOMr. William J. Enright MBA
E-voting on sharesClick here to vote

Key Management of Barinthus Biotherapeutics Plc

Name

Title

Ms. Sarah Gilbert

Co-Founder

Mr. Adrian Hill Ph.D.

Co-Founder & Scientific Advisor

Dr. Geoffrey Lynn M.D., Ph.D.

Chief Scientific Officer

Dr. Leon Hooftman M.D.

Chief Medical Officer

Mr. William J. Enright MBA

CEO, Director & Principal Financial Officer

Ms. Gemma Brown

Principal Accounting Officer

FAQs

What is Barinthus Biotherapeutics Plc share price today?

Barinthus Biotherapeutics Plc share price today is $1.05 as on at the close of the market. Barinthus Biotherapeutics Plc share today touched a day high of $1.12 and a low of $1.04.

What is the 52 week high and 52 week low for Barinthus Biotherapeutics Plc share?

Barinthus Biotherapeutics Plc share touched a 52 week high of $2.92 on and a 52 week low of $0.64 on . Barinthus Biotherapeutics Plc stock price today i.e. is closed at $1.05,which is 64.04% down from its 52 week high and 64.06% up from its 52 week low.

What is Barinthus Biotherapeutics Plc's market capitalisation today?

Barinthus Biotherapeutics Plc market capitalisation is $0.00T as on .

How to invest in Barinthus Biotherapeutics Plc Stock (BRNS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Barinthus Biotherapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Barinthus Biotherapeutics Plc Shares that will get you 1.4286 shares as per Barinthus Biotherapeutics Plc share price of $1.05 per share as on September 16, 2025 at 1:27 am IST.

What is the minimum amount required to buy Barinthus Biotherapeutics Plc Stock (BRNS) from India?

Indian investors can start investing in Barinthus Biotherapeutics Plc (BRNS) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Barinthus Biotherapeutics Plc stock (as per the Rupee-Dollar exchange rate as on ). Based on Barinthus Biotherapeutics Plc share’s latest price of $1.05 as on September 16, 2025 at 1:27 am IST, you will get 9.5238 shares of Barinthus Biotherapeutics Plc. Learn more about fractional shares .